Thematic initiatives: Hub VPH, TWB, and APM
BIOASTER is one of the founding partners of the HUB VPH (Veterinary Public Health). The HUB VPH (Veterinary Public Health) is an unprecedented public-private initiative that involves nine major players in the health ecosystem in the Auvergne-Rhône-Alpes region.
This first Veterinary Public Health hub was created on the basis of a common desire: to become a world-class reference center for Veterinary Public Health, and was driven by the strong collaborative tradition in the Auvergne-Rhône-Alpes region and recognition of the importance of addressing international Veterinary Public Health issues.
BIOASTER is a member of the Toulouse White Biotechnology (TWB) consortium. TWB provides concrete assistance for companies and biotechnology entrepreneurs in the development of products and processes using bio-sourced raw materials, from the laboratory to the pre-industrial pilot stage. As a member of the Strategic Orientation Committee, BIOASTER contributes to the definition of TWB’s roadmap and to the annual selection of self-financed public research projects, using its knowledge and vision regarding biotechnology and technological tools.
BIOASTER is one of the founders of the Alliance Promotion Microbiote (APM). The APM was instigated not only to consolidate the existing ecosystem, but also to develop it, strengthen it, and accelerate the deployment of potential approaches to address the key challenges of attractiveness, national interest, health independence, and access to innovative therapies in France.
As an associate member of the Biotech companies in Europe combating AntiMicrobial Resistance (BEAM) alliance, BIOASTER contributes to the federation of European initiatives to tackle antimicrobial resistance. BIOASTER’s relationships with some of the SME participants in the BEAM alliance manifest as joint research projects, such as DACCAR with Da Volterra and PhagUTI with Pherecydes Pharma.
Cynbiome® is a preclinical network dedicated to research into the microbiome that aims to capitalize on the richness and complementarity of players specializing in fields such as high-throughput sequencing, biomanufacturing, imaging, microfluidics, specific analyses, biomarkers, and preclinical and clinical activities.
Cynbiome® undertakes preclinical R&D activities, focusing on the microbiome and infectious diseases.
BIOASTER is a player in the development of innovative technologies for healthcare purposes, bringing its expertise, means, and resources to the pursuit of these objectives, and is an enthusiastic participant in the partnership and collaborative approaches to the development of common objectives and projects.
Pharmabiotic Research Institute
The PRI was founded to make Microbial Medicinal Products a therapeutic reality in Europe. The PRI believes that the microbiome represents the future of human medicine. The members have stakes in the regulatory, technical, and collaborative efforts regarding the microbiome and human health space. Dr Vincent Thomas, Head of the Microbiota Program at BIOASTER, is a PRI Board Member.